HANTZ FINANCIAL SERVICES, INC.
Position in DNLI — Denali Therapeutics Inc.
CIK 1071061
SOUTHFIELD, MI
Position in DNLI
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$1
-$1,093 QoQ
Shares Held
57
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#290
of 290 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026HANTZ FINANCIAL SERVICES, INC. holds $21,275,017 across 57 Biotechnology names. DNLI ranks #55 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
15,883 | $4,781,259 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
58,496 | $4,578,481 | |
| 3 | ARGX |
Argenx SE
|
2,816 | $2,612,600 | |
| 4 | ROIV |
Roivant Sciences Ltd.
|
34,865 | $1,233,872 | |
| 5 | JAZZ |
Jazz Pharmaceuticals plc
|
3,961 | $954,482 | |
| 6 | EXEL |
Exelixis, Inc.
|
16,074 | $874,586 | |
| 7 | CYTK |
Cytokinetics Inc
|
10,063 | $857,266 | |
| 8 | BMRN |
Biomarin Pharmaceutical Inc
|
11,424 | $653,681 |
All Filings in DNLI
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1 | 57 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $1,094 | 57 | Shares | Sole | 2026-05-01 | |
| 2025-12-31 | $941 | 57 | Shares | Sole | 2026-02-09 | |
| No filing history on record for this holder in this stock. | ||||||